度伐利尤单抗联合西妥昔单抗和放疗治疗局部晚期头颈部鳞状细胞癌:一项1/2期试验
这项1/2期试验在9例高危局部晚期头颈部鳞状细胞癌患者中,将度伐利尤单抗(每28天1500 mg)与放疗和西妥昔单抗联用,主要终点为2年无进展生存率。由于监管问题、新冠疫情及支持公司撤回度伐利尤单抗,研究于2021年4月提前终止。中位随访11.5个月时,1年和2年无进展生存率分别为77.7%和58.3%,唯一剂量限制性毒性为持续14天的4级黏膜炎。
要点
- 9例患者中位随访11.5个月,1年和2年无进展生存率分别为77.7%和58.3%。
- 唯一剂量限制性毒性为持续14天的4级黏膜炎,未出现放疗中断。
- 西妥昔单抗和度伐利尤单抗的平均相对剂量强度分别为85.5%和87.5%。
核心结论
- 尽管受小样本量限制,作者初步观察到度伐利尤单抗联合西妥昔单抗和放疗的抗肿瘤活性及耐受性,可能值得进一步研究。
研究设计与样本
- 1/2期试验,计划进行安全性导入,因监管问题无法开放多中心、新冠疫情及支持公司撤回度伐利尤单抗,研究于2021年4月提前终止。
- 2019年7月至2020年8月共入组9例高危局部晚期头颈部鳞状细胞癌患者,所有肿瘤PD-L1联合阳性评分>1。
- 度伐利尤单抗固定剂量1500 mg每28天一次,从联合治疗第一周起与放疗和西妥昔单抗同步给予,放疗完成后辅助度伐利尤单抗最长至6个月。
- 主要终点为2年无进展生存率。
主要发现
- 西妥昔单抗和度伐利尤单抗的平均相对剂量强度分别为85.5%和87.5%,未出现放疗中断。
- 唯一报告的剂量限制性毒性为持续14天的4级黏膜炎。
- 中位随访11.5个月(IQR 7.7-16.7)时,9例中6例存活患者均无病,1年和2年无进展生存率分别为77.7%和58.3%。
- 所有病例均对选择性淋巴结区域进行选择性保护,累积平均剂量为37.6 Gy(SD 8.4)。
局限性
- 作者指出研究受小样本量限制。
- 研究因监管问题无法开放多中心、新冠疫情及支持公司撤回度伐利尤单抗而于2021年4月提前终止。
- 作者结论为初步观察可能值得进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To report on the anti-tumor activity of a novel combination in high-risk locally advanced head and neck squamous cell carcinoma. MATERIALS AND METHODS: At a fixed dose of 1500 mg every 28 days, anti PD-L1 Durvalumab was given concomitantly to Radiotherapy and Cetuximab starting from the first week of combined treatment, followed by adjuvant Durvalumab to a maximum of 6 months after completion of radiation. The primary endpoint of the study was 2-year progression-free survival (PFS). A safety run-in was planned. Due to regulatory issues which prevented from opening multiple centers, COVID-19 pandemic and withdrawal of Durvalumab from supporting company, the study was prematurely terminated in April 2021. RESULTS: Between July 2019 and August 2020, 9 patients were enrolled in the study. All tumors had a PD-L1 Combined Positive Score > 1. Optimal drug exposure was observed, with mean relative dose intensity of 85.5% and 87.5% for Cetuximab and Durvalumab, respectively. No radiation breaks were necessary. A grade 4 mucositis lasting for 14 days corresponded to the only dose limiting toxicity we reported. At a median follow-up of 11.5 months (IQR 7.7-16.7) all surviving patients (6 out of 9) are disease-free, with 1 and 2-year PFS rates of 77.7% and 58.3%, respectively. A selective sparing of node levels in the elective volume was performed in all cases, yielding a cumulative mean dose of 37.6 Gy (SD 8.4). CONCLUSION: Albeit limited by the small sample size, our preliminary observation of anti-tumor activity and tolerability of Durvalumab in addition to Cetuximab and radiation may warrant further investigations.
引用
- Bonomo P, Desideri I, Mangoni M, et al. Durvalumab with cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: A phase 1/2 trial. Radiother Oncol. 2022. PMID: 35157978. doi:10.1016/j.radonc.2022.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。